Loading patent…
AssigneeIlypsa, Inc.
InventorsEric Connor, Dominique Charmot, Han Ting Chang, Florence Roger, Gerrit Klearner, Son Hoai Nguyen
Estimating the term…
Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.
A pharmaceutical composition comprising a phosphate binding crosslinked amine polymer as an active ingredient and a pharmaceutically acceptable excipient, the crosslinked amine polymer comprising a polyamine polymer derived from the polymerization of an amine monomer, the polyamine polymer being crosslinked with a crosslinking agent, wherein the crosslinked amine polymer has a gel pore volume and less than about 20% of the gel pore volume is accessible to non-interacting solutes of molecular weight greater than about 200 as measured in a physiological medium which is isotonic and neutral pH.
A pharmaceutical composition comprising a phosphate binding crosslinked amine polymer as an active ingredient and a pharmaceutically acceptable excipient, the crosslinked amine polymer comprising a polyamine polymer derived from the polymerization of an amine monomer, the polyamine polymer being crosslinked with a crosslinking agent, wherein the crosslinked amine polymer has an ion-binding interference for phosphate lower than about 60% when measured in a gastrointestinal simulant, relative to a non-interfering buffer.
The pharmaceutical composition comprising a phosphate binding particulate crosslinked amine polymer as an active ingredient and a pharmaceutically acceptable excipient, the polymer particles having a size in the range of 5 to 500 microns, the crosslinked amine polymer comprising a polyamine polymer derived from the polymerization of an amine monomer, the polyamine polymer being crosslinked with a crosslinking agent, wherein the crosslinked amine polymer has a gel pore volume and less than about 20% of the gel pore volume is accessible to non-interacting solutes of molecular weight greater than about 200 as measured in a physiological medium which is isotonic and neutral pH.
Dependencies are inferred from the claim text.